Olanzapine + Fluoxetine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 6 mg + 25 mg , 3mg+25mg
Reference Brands: Symbyax (USA)
Category:
Antipsychotropic Drugs
Olanzapine + Fluoxetine Hydrochloride is available in Capsules
and strengths such as 6 mg + 25 mg , 3mg+25mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Olanzapine + Fluoxetine Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Olanzapine + Fluoxetine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Olanzapine/fluoxetine is a fixed-dose combination medication used for the treatment of depressive episodes associated with bipolar I disorder and for treatment-resistant depression in adults. Marketed under the brand name Symbyax and developed by Eli Lilly and Company, this combination brings together two well-established psychotropic agents with complementary mechanisms of action.
Olanzapine is an atypical antipsychotic that helps stabilize mood by modulating dopamine and serotonin receptors in the brain, while fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that enhances serotonin levels to alleviate depressive symptoms. By combining these agents in a single formulation, Symbyax addresses both mood dysregulation and depressive features more effectively than antidepressant therapy alone in certain patients.
Symbyax is administered orally and is typically prescribed when standard antidepressant treatments have not provided sufficient benefit. The fixed-dose formulation supports consistent dosing and improved treatment adherence. As with other psychotropic medications, patients receiving olanzapine/fluoxetine require clinical monitoring due to potential adverse effects related to metabolic changes, sedation, and central nervous system effects. Overall, Symbyax offers an important therapeutic option for managing complex depressive conditions requiring combined antipsychotic and antidepressant treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing